667 related articles for article (PubMed ID: 15935380)
1. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
2. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
[TBL] [Abstract][Full Text] [Related]
3. Formation of the single-layer beta-sheet of Borrelia burgdorferi OspA in the absence of the C-terminal capping globular domain.
Huang X; Nakagawa T; Tamura A; Link K; Koide A; Koide S
J Mol Biol; 2001 Apr; 308(2):367-75. PubMed ID: 11327773
[TBL] [Abstract][Full Text] [Related]
4. NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies.
Huang X; Yang X; Luft BJ; Koide S
J Mol Biol; 1998 Aug; 281(1):61-7. PubMed ID: 9680475
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice.
Bockenstedt LK; Fikrig E; Barthold SW; Flavell RA; Kantor FS
J Immunol; 1996 Dec; 157(12):5496-502. PubMed ID: 8955199
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an anti-Borrelia burgdorferi OspA conformational epitope by limited proteolysis of monoclonal antibody-bound antigen and mass spectrometric peptide mapping.
Legros V; Jolivet-Reynaud C; Battail-Poirot N; Saint-Pierre C; Forest E
Protein Sci; 2000 May; 9(5):1002-10. PubMed ID: 10850810
[TBL] [Abstract][Full Text] [Related]
7. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
[TBL] [Abstract][Full Text] [Related]
8. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
9. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
Izac JR; Oliver LD; Earnhart CG; Marconi RT
Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
[TBL] [Abstract][Full Text] [Related]
10. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
[TBL] [Abstract][Full Text] [Related]
11. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.
Lovrich SD; Jobe DA; Schell RF; Callister SM
Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749
[TBL] [Abstract][Full Text] [Related]
12. Approaches toward the directed design of a vaccine against Borrelia burgdorferi.
Luft BJ; Dunn JJ; Lawson CL
J Infect Dis; 2002 Feb; 185 Suppl 1():S46-51. PubMed ID: 11865439
[TBL] [Abstract][Full Text] [Related]
13. Crystallization and preliminary X-ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment.
Li H; Lawson CL
J Struct Biol; 1995; 115(3):335-7. PubMed ID: 8573475
[TBL] [Abstract][Full Text] [Related]
14. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
16. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice.
Alexopoulou L; Thomas V; Schnare M; Lobet Y; Anguita J; Schoen RT; Medzhitov R; Fikrig E; Flavell RA
Nat Med; 2002 Aug; 8(8):878-84. PubMed ID: 12091878
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato.
Drouin EE; Glickstein LJ; Steere AC
J Autoimmun; 2004 Nov; 23(3):281-92. PubMed ID: 15501399
[TBL] [Abstract][Full Text] [Related]
18. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice.
Bockenstedt LK; Fikrig E; Barthold SW; Kantor FS; Flavell RA
J Immunol; 1993 Jul; 151(2):900-6. PubMed ID: 8335917
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
20. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
